文献速递脊柱关节炎

欧洲未使用生物制剂的脊柱关节炎患者起始TNF抑制剂治疗:基线特征、治疗留存与应答的时间趋势

European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

该研究汇总15个欧洲国家常规诊疗中未使用生物制剂的axSpA和PsA患者前瞻性数据,按TNFi起始年份分为1999-2008、2009-2014和2015-2018三个队列,评估6、12、24个月留存率、缓解率和应答率。结果显示近年起始治疗时病程更短、留存率下降、缓解率升高,提示临床医生采用了更积极的治疗策略。

要点

  • 队列A(1999-2008)患者病程长于队列B和C,axSpA中男性及HLA-B27阳性比例最高。
  • axSpA/PsA留存率在队列A最高,队列B与C间仅略有差异。
  • axSpA中队列A在24个月时疾病活动度最高,缓解率和应答率最低。

核心结论

  • 过去数十年间临床医生对脊柱关节炎采用了更积极的治疗策略,表现为起始治疗时病程更短、留存率下降及近年缓解率升高。

研究设计与样本

  • 汇总15个欧洲国家常规诊疗中前瞻性收集的未使用生物制剂的axSpA和PsA患者数据。
  • 按TNFi起始年份定义三个队列:A(1999-2008)、B(2009-2014)、C(2015-2018)。
  • 共纳入27 149例axSpA和17 446例PsA患者,在6、12和24个月评估留存率、缓解率和应答率。

主要发现

  • 队列A患者病程长于队列B和C。
  • axSpA中队列A男性及HLA-B27阳性患者比例最大,PsA中队列A基线疾病活动度最高。
  • axSpA/PsA留存率在队列A最高,队列B与C间仅略有差异。
  • 所有队列疾病活动度从0至6个月显著下降;axSpA中队列A在24个月疾病活动度最高,缓解率和应答率最低。
  • PsA中队列A在6和12个月缓解率趋于最低;各队列应答率在所有时间点相当,24个月时队列间疾病活动度差异较小。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate time trends in baseline characteristics and retention, remission and response rates in bio-naïve axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) patients initiating TNF inhibitor (TNFi) treatment. METHODS: Prospectively collected data on bio-naïve axSpA and PsA patients from routine care in 15 European countries were pooled. Three cohorts were defined according to year of TNFi initiation: A (1999-2008), B (2009-2014) and C (2015-2018). Retention, remission and response rates were assessed at 6, 12 and 24 months. RESULTS: In total, 27 149 axSpA and 17 446 PsA patients were included. Cohort A patients had longer disease duration compared with B and C. In axSpA, cohort A had the largest proportion of male and HLA-B27 positive patients. In PsA, baseline disease activity was highest in cohort A. Retention rates in axSpA/PsA were highest in cohort A and differed only slightly between B and C. For all cohorts, disease activity decreased markedly from 0 to 6 months. In axSpA, disease activity at 24 months was highest in cohort A, where also remission and response rates were lowest. In PsA, remission rates at 6 and 12 months tended to be lowest in cohort A. Response rates were at all time points comparable across cohorts, and less between-cohort disease activity differences were seen at 24 months. CONCLUSION: Our findings indicate that over the past decades, clinicians have implemented more aggressive treatment strategies in spondyloarthritis. This was illustrated by shorter disease duration at treatment initiation, decreased retention rates and higher remission rates during recent years.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Christiansen SN, Ørnbjerg LM, Rasmussen SH, et al. European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response. Rheumatology (Oxford). 2022. PMID: 34940840. doi:10.1093/rheumatology/keab945

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。